Latest filing published 12 Jul 2018 for Kiora Pharmaceuticals INC.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -53.8%Entry US$32,400.00 · Close at T+365 US$14,963.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Paul G. Chaney: trading record in brief
Paul G. Chaney discloses dealings in Kiora Pharmaceuticals Inc to SEC (Form 4). In total, 5 filings cover trades dated from 19 February 2015 to 10 July 2018.
No open-market sale appears; the market trades are 1 purchase worth €44k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 3 share grants and 1 option exercise.
On 12 July 2018 came the latest disclosure, a share grant in Kiora Pharmaceuticals Inc. The last insider purchase was made public on 23 February 2015, 4,277 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Paul G. Chaney
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 50,000 shares0Common StockSEC:0001144204-18-038186:0
- 17,570 shares@ US$0.65100.0% of flowCommon StockSEC:0001144204-17-031102:0
- 7,408 shares0Common StockSEC:0001144204-15-053237:0
- 15,326 shares0Common StockSEC:0001144204-15-027715:0
- 8,333 shares@ US$6.00Common StockSEC:0001144204-15-011511:0Canonical exit: 20 May 2015 (T+90)
5 of 5 declarations